Journal
FEBS JOURNAL
Volume 282, Issue 24, Pages 4679-4691Publisher
WILEY
DOI: 10.1111/febs.13530
Keywords
broadly neutralizing antibody; envelope trimer; glycosylation; HIV; vaccine
Categories
Funding
- Medical Research Council Career Development Award [MR/K024426/1]
- MRC [MR/K024426/1] Funding Source: UKRI
- Medical Research Council [MR/K024426/1] Funding Source: researchfish
Ask authors/readers for more resources
The HIV envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bnAbs). HIV Env is one of the most heavily glycosylated proteins known, with approximately half of its mass consisting of host-derived N-linked glycans. The high density of glycans creates a shield that impedes antibody recognition but, critically, some of the most potent and broadly active bnAbs have evolved to recognize epitopes formed by these glycans. Although the virus hijacks the host protein synthesis and glycosylation machinery to generate glycosylated HIV Env, studies have shown that HIV Env glycosylation diverges from that typically observed on host-derived glycoproteins. In particular, the high density of glycans leads to a nonself motif of underprocessed oligomannose-type glycans that forms the target of some of the most broad and potent HIV bnAbs. This review discusses the changing perception of the HIV glycan shield, and summarizes the protein-directed and cell-directed factors controlling HIV Env glycosylation that impact on HIV bnAb recognition and HIV vaccine design strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available